, Volume 219, Issue 4, pp 1099–1109 | Cite as

Behavioral and molecular evidence for psychotropic effects in l-theanine

  • Chisato Wakabayashi
  • Tadahiro Numakawa
  • Midori Ninomiya
  • Shuichi Chiba
  • Hiroshi KunugiEmail author
Original Investigation



l-Theanine (N-ethyl-l-glutamine) is an amino acid uniquely found in green tea and historically considered to be a relaxing agent. It is a glutamate derivative and has an affinity for glutamatergic receptors. However, its psychotropic effects remain unclear.


To elucidate effects of l-theanine on psychiatric disease-related behaviors in mice and its molecular basis focusing on brain-derived neurotrophic factor (BDNF) and N-methyl-d-aspartate (NMDA) receptor.


We examined the effects of l-theanine on behaviors in mice by using the open-field test (OFT), forced swim test (FST), elevated plus-maze test (EPMT), and prepulse inhibition (PPI) of acoustic startle. By western blot analysis, we looked at the effect of l-theanine on the expression of BDNF and related proteins in the hippocampus and cerebral cortex. To determine whether l-theanine has agonistic action on the NMDA receptor, we performed Fluo-3 intracellular Ca2+ imaging in cultured cortical neurons.


Single administration of l-theanine significantly attenuated MK-801-induced deficits in PPI. Subchronic administration (3-week duration) of l-theanine significantly reduced immobility time in the FST and improved baseline PPI. Western blotting analysis showed increased expression of BDNF protein in the hippocampus after subchronic administration of l-theanine. In cultured cortical neurons, l-theanine significantly increased the intracellular Ca2+ concentration, and this increase was suppressed by competitive and non-competitive NMDA receptor antagonists (AP-5 and MK-801, respectively).


Our results suggest that l-theanine has antipsychotic-like and possibly antidepressant-like effects. It exerts these effects, at least in part, through induction of BDNF in the hippocampus and the agonistic action of l-theanine on the NMDA receptor.


l-theanine MK-801 (dizocilpine) N-methyl d-aspartate (NMDA) receptor Schizophrenia Prepulse inhibition Brain-derived neurotrophic factor (BDNF) Behavior Glutamate Antidepressant 



Open-field test


Prepulse inhibition


Forced swim test


Elevated plus-maze test




Gamma-aminobutyric acid


Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid


Brain-derived neurotrophic factor




d-(−)-2-amino-5-phosphonopentanoic acid



This study was supported by the Health and Labor Sciences Research Grants (Comprehensive Research on Disability, Health, and Welfare), Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), CREST, JST, and “Understanding of molecular and environmental bases for brain health” carried out under the Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Financial disclosures

All authors repot no biomedical financial interests or potential conflicts of interest.

Supplementary material

213_2011_2440_MOESM1_ESM.doc (178 kb)
ESM 1 (DOC 178 kb)


  1. Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181–188PubMedCrossRefGoogle Scholar
  2. Braff DL, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR (2001) Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49:171–178PubMedCrossRefGoogle Scholar
  3. Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C (2005) The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 80:591–596PubMedCrossRefGoogle Scholar
  4. Castren E, Rantamaki T (2010) The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 70:289–297PubMedCrossRefGoogle Scholar
  5. Castren E, Pitkanen M, Sirvio J, Parsadanian A, Lindholm D, Thoenen H, Riekkinen PJ (1993) The induction of LTP increases BDNF and NGF mRNA but decreases NT-3 mRNA in the dentate gyrus. Neuroreport 4:895–898PubMedCrossRefGoogle Scholar
  6. de Mejia EG, Ramirez-Mares MV, Puangpraphant S (2009) Bioactive components of tea: cancer, inflammation and behavior. Brain Behav Immun 23:721–731PubMedCrossRefGoogle Scholar
  7. DeCoster MA, Lambeau G, Lazdunski M, Bazan NG (2002) Secreted phospholipase A2 potentiates glutamate-induced calcium increase and cell death in primary neuronal cultures. J Neurosci Res 67:634–645PubMedCrossRefGoogle Scholar
  8. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116–1127PubMedCrossRefGoogle Scholar
  9. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J (2001) Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52:79–86PubMedCrossRefGoogle Scholar
  10. Egashira N, Hayakawa K, Osajima M, Mishima K, Iwasaki K, Oishi R, Fujiwara M (2007) Involvement of GABAA receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci 105:211–214PubMedCrossRefGoogle Scholar
  11. Egashira N, Ishigami N, Pu F, Mishima K, Iwasaki K, Orito K, Oishi R, Fujiwara M (2008) Theanine prevents memory impairment induced by repeated cerebral ischemia in rats. Phytother Res 22:65–68PubMedCrossRefGoogle Scholar
  12. Fejgin K, Safonov S, Palsson E, Wass C, Engel JA, Svensson L, Klamer D (2007) The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 191:377–385CrossRefGoogle Scholar
  13. Furuta M, Kunugi H (2008) Animal models for schizophrenia: a brief overview. In: Turck CW (ed) Biomarkers for psychiatric disorders. Springer, New York, pp 163–184Google Scholar
  14. Geyer MA (2006) The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotox Res 10:211–220PubMedCrossRefGoogle Scholar
  15. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117–154CrossRefGoogle Scholar
  16. Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377PubMedCrossRefGoogle Scholar
  17. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2010) Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry (in press)Google Scholar
  18. Heese T, Jenkinson J, Love C, Milam R, Perkins L, Adams C, McCall S, Ceremuga TE (2009) Anxiolytic effects of l-theanine—a component of green tea—when combined with midazolam, in the male Sprague–Dawley rat. AANA J 77:445–449PubMedGoogle Scholar
  19. Ishii D, Matsuzawa D, Kanahara N, Matsuda S, Sutoh C, Ohtsuka H, Nakazawa K, Kohno M, Hashimoto K, Iyo M, Shimizu E (2010) Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway. Neurosci Lett 471:53–57PubMedCrossRefGoogle Scholar
  20. Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308PubMedGoogle Scholar
  21. Juneja L, Chu D, Okubo T, Nagato Y, Yokogoshi H (1999) l-theanine—a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci Technol 10:199–204CrossRefGoogle Scholar
  22. Kakuda T (2002) Neuroprotective effects of the green tea components theanine and catechins. Biol Pharm Bull 25:1513–1518PubMedCrossRefGoogle Scholar
  23. Kakuda T, Nozawa A, Sugimoto A, Niino H (2002) Inhibition by theanine of binding of [3H]AMPA, [3H]kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci Biotechnol Biochem 66:2683–2686PubMedCrossRefGoogle Scholar
  24. Kanahara N, Shimizu E, Ohgake S, Fujita Y, Kohno M, Hashimoto T, Matsuzawa D, Shirayama Y, Hashimoto K, Iyo M (2008) Glycine and d-serine, but not d-cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl) 198:363–374CrossRefGoogle Scholar
  25. Kimura K, Ozeki M, Juneja LR, Ohira H (2007) l-Theanine reduces psychological and physiological stress responses. Biol Psychol 74:39–45PubMedCrossRefGoogle Scholar
  26. Kretschmer BD, Koch M (1997) Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology (Berl) 130:131–138CrossRefGoogle Scholar
  27. Kumamaru E, Numakawa T, Adachi N, Yagasaki Y, Izumi A, Niyaz M, Kudo M, Kunugi H (2008) Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. Mol Endocrinol 22:546–558PubMedCrossRefGoogle Scholar
  28. Kunugi H, Tanaka M, Hori H, Hashimoto R, Saitoh O, Hironaka N (2007) Prepulse inhibition of acoustic startle in Japanese patients with chronic schizophrenia. Neurosci Res 59:23–28PubMedCrossRefGoogle Scholar
  29. Kunugi H, Hori H, Adachi N, Numakawa T (2010) Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 64:447–459PubMedCrossRefGoogle Scholar
  30. Lipina T, Labrie V, Weiner I, Roder J (2005) Modulators of the glycine site on NMDA receptors, d-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology (Berl) 179:54–67CrossRefGoogle Scholar
  31. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92:180–185Google Scholar
  32. Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL, Nathan PJ (2004) The acute effects of l-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum Psychopharmacol 19:457–465PubMedCrossRefGoogle Scholar
  33. Mansbach RS, Geyer MA (1989) Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2:299–308PubMedCrossRefGoogle Scholar
  34. Martinowich K, Manji H, Lu B (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci 10:1089–1093PubMedCrossRefGoogle Scholar
  35. Matsumoto T, Numakawa T, Yokomaku D, Adachi N, Yamagishi S, Numakawa Y, Kunugi H, Taguchi T (2006) Brain-derived neurotrophic factor-induced potentiation of glutamate and GABA release: different dependency on signaling pathways and neuronal activity. Mol Cell Neurosci 31:70–84PubMedCrossRefGoogle Scholar
  36. Mattson MP (2008) Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 1144:97–112PubMedCrossRefGoogle Scholar
  37. Nathan PJ, Lu K, Gray M, Oliver C (2006) The neuropharmacology of l-theanine (N-ethyl-l-glutamine): a possible neuroprotective and cognitive enhancing agent. J Herb Pharmacother 6:21–30PubMedGoogle Scholar
  38. Nibuya M, Morinobu S, Duman RS (1995) Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci 15:7539–7547PubMedGoogle Scholar
  39. Nobre AC, Rao A, Owen GN (2008) l-theanine, a natural constituent in tea, and its effect on mental state. Asia Pac J Clin Nutr 17(Suppl 1):167–168PubMedGoogle Scholar
  40. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995) Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116:2531–2537PubMedGoogle Scholar
  41. Numakawa T, Yamagishi S, Adachi N, Matsumoto T, Yokomaku D, Yamada M, Hatanaka H (2002) Brain-derived neurotrophic factor-induced potentiation of Ca2+ oscillations in developing cortical neurons. J Biol Chem 277:6520–6529PubMedCrossRefGoogle Scholar
  42. Numakawa T, Nakayama H, Suzuki S, Kubo T, Nara F, Numakawa Y, Yokomaku D, Araki T, Ishimoto T, Ogura A, Taguchi T (2003) Nerve growth factor-induced glutamate release is via p75 receptor, ceramide, and Ca2+ from ryanodine receptor in developing cerebellar neurons. J Biol Chem 278:41259–41269PubMedCrossRefGoogle Scholar
  43. Numakawa T, Ishimoto T, Suzuki S, Numakawa Y, Adachi N, Matsumoto T, Yokomaku D, Koshimizu H, Fujimori KE, Hashimoto R, Taguchi T, Kunugi H (2004) Neuronal roles of the integrin-associated protein (IAP/CD47) in developing cortical neurons. J Biol Chem 279:43245–43253PubMedCrossRefGoogle Scholar
  44. Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H (2009) Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci USA 106:647–652PubMedCrossRefGoogle Scholar
  45. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, Kunugi H (2010) BDNF function and intracellular signaling in neurons. Histol Histopathol 25:237–258PubMedGoogle Scholar
  46. Park SK, Jung IC, Lee WK, Lee YS, Park HK, Go HJ, Kim K, Lim NK, Hong JT, Ly SY, Rho SS (2011) A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food 14:334–343PubMedCrossRefGoogle Scholar
  47. Patterson SL, Grover LM, Schwartzkroin PA, Bothwell M (1992) Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron 9:1081–1088PubMedCrossRefGoogle Scholar
  48. Petit-Demouliere B, Chenu F, Bourin M (2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 177:245–255CrossRefGoogle Scholar
  49. Pillai A (2008) Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals 16:183–193PubMedCrossRefGoogle Scholar
  50. Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730–732PubMedCrossRefGoogle Scholar
  51. Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V (2011) l-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 72:34–42PubMedCrossRefGoogle Scholar
  52. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805–809PubMedCrossRefGoogle Scholar
  53. Shieh PB, Hu SC, Bobb K, Timmusk T, Ghosh A (1998) Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20:727–740PubMedCrossRefGoogle Scholar
  54. Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 156:194–215CrossRefGoogle Scholar
  55. Takeuchi Y, Yamamoto H, Miyakawa T, Miyamoto E (2000) Increase of brain-derived neurotrophic factor gene expression in NG108-15 cells by the nuclear isoforms of Ca2+/calmodulin-dependent protein kinase II. J Neurochem 74:1913–1922PubMedCrossRefGoogle Scholar
  56. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709–726PubMedCrossRefGoogle Scholar
  57. Weiner I, Schiller D, Gaisler-Salomon I, Green A, Joel D (2003) A comparison of drug effects in latent inhibition and the forced swim test differentiates between the typical antipsychotic haloperidol, the atypical antipsychotics clozapine and olanzapine, and the antidepressants imipramine and paroxetine. Behav Pharmacol 14:215–222PubMedCrossRefGoogle Scholar
  58. Wiley JL, Kennedy KL (2002) Evaluation of the efficacy of antipsychotic attenuation of phencyclidine-disrupted prepulse inhibition in rats. J Neural Transm 109:523–535PubMedCrossRefGoogle Scholar
  59. Yamada T, Terashima T, Wada K, Ueda S, Ito M, Okubo T, Juneja LR, Yokogoshi H (2007) Theanine, r-glutamylethylamide, increases neurotransmission concentrations and neurotrophin mRNA levels in the brain during lactation. Life Sci 81:1247–1255PubMedCrossRefGoogle Scholar
  60. Yin C, Gou L, Liu Y, Yin X, Zhang L, Jia G, Zhuang X (2011) Antidepressant-like effects of l-theanine in the forced swim and tail suspension tests in mice. Phytother Res (in press)Google Scholar
  61. Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T (1998a) Effect of theanine, r-glutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem Res 23:667–673PubMedCrossRefGoogle Scholar
  62. Yokogoshi H, Mochizuki M, Saitoh K (1998b) Theanine-induced reduction of brain serotonin concentration in rats. Biosci Biotechnol Biochem 62:816–817PubMedCrossRefGoogle Scholar
  63. Zafra F, Castren E, Thoenen H, Lindholm D (1991) Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. Proc Natl Acad Sci USA 88:10037–10041PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Chisato Wakabayashi
    • 1
  • Tadahiro Numakawa
    • 1
    • 2
  • Midori Ninomiya
    • 1
  • Shuichi Chiba
    • 1
  • Hiroshi Kunugi
    • 1
    • 2
    Email author
  1. 1.Department of Mental Disorder ResearchNational Institute of Neuroscience, National Center of Neurology and PsychiatryTokyoJapan
  2. 2.Core Research for Evolutional Science and Technology Program (CREST)Japan Science and Technology Agency (JST)TokyoJapan

Personalised recommendations